Cabazitaxel exhibits more favorable molecular changes compared to other taxanes in androgen‐independent prostate cancer cells
- 24 June 2020
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 34 (9) , e22542
Abstract
Taxane‐based chemotherapy drugs (cabazitaxel, docetaxel, and paclitaxel) are microtubule inhibitors, which are effectively and frequently used to treat metastatic prostate cancer (PCa). Among these, cabazitaxel is offered as a new therapeutic option for patients with metastatic castration‐resistant PC as that are resistant to other taxanes. Here, we investigated the cellular and molecular changes in response to cabazitaxel in comparison with docetaxel and paclitaxel in androgen‐independent human PCas. The androgen‐independent human PCa cell lines, PC3 and DU145, were treated with 1 to 5nM cabazitaxel, docetaxel, or paclitaxel, and assessed for cell viability (MTT assay), colony forming ability and migration (scratch assay). The induction of apoptosis was determined through measurement of mitochondrial membrane potential (JC‐1 assay) and caspase‐3 activity assay. The protein expression changes (caspase‐3, caspase‐8, Bax, Bcl‐2, β‐tubulin, nuclear factor‐κB [NF‐κB/p50, NF‐κB/p65], vascular endothelial growth factor, WNT1‐inducible signaling pathway protein‐1 [WISP1], transforming growth factor β [TGF‐β]) in response to drug treatment were screened via western blotting. Under our experimental conditions, all taxanes significantly reduced WISP1 and TGF‐β expressions, suggesting an anti‐metastatic/antiangiogenic effect for these drugs. On the other hand, cabazitaxel induced more cell death and inhibited colony formation compared to docetaxel or paclitaxel. The highest fold change in caspase‐3 activity and Bax/Bcl‐2 ratio was also detected in response to cabazitaxel. Furthermore, the induction of β‐tubulin expression was lower in cabazitaxel‐treated cells relative to the other taxanes. In summary, cabazitaxel shows molecular changes in favor of killing PCa cells compared to other taxanes, at least for the parameters analyzed herein. The differences with other taxanes may be important while designing other studies or in clinical settings.Keywords
Funding Information
- Adnan Menderes Üniversitesi (TPF‐18012)
This publication has 52 references indexed in Scilit:
- Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospectsJournal of Pharmacology and Pharmacotherapeutics, 2013
- WISP1/CCN4: A Potential Target for Inhibiting Prostate Cancer Growth and Spread to BonePLOS ONE, 2013
- Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?Cancer Chemotherapy and Pharmacology, 2012
- Characterisation and manipulation of docetaxel resistant prostate cancer cell linesMolecular Cancer, 2011
- Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate CancerCancer Research, 2009
- The NF- B Family of Transcription Factors and Its RegulationCold Spring Harbor Perspectives in Biology, 2009
- RNA Interference-directed Knockdown of Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receptor Inhibits Prostate Cancer Cell Invasion, Survival, and Tumorigenicity in VivoJournal of Biological Chemistry, 2005
- Tumour-cell invasion and migration: diversity and escape mechanismsNature Reviews Cancer, 2003
- Caspases: opening the boxes and interpreting the arrowsCell Death & Differentiation, 2002
- Taxol selectively blocks microtubule dependent NF-κB activation by phorbol ester via inhibition of IκBα phosphorylation and degradationOncogene, 1999